New drug development
- 31 December 1991
- journal article
- review article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (3) , 377-380
- https://doi.org/10.1016/0277-5379(91)90550-w
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- In Defense of Cell-Line ScreeningJNCI Journal of the National Cancer Institute, 1990
- 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistanceEuropean Journal of Cancer and Clinical Oncology, 1990
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989
- Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic ImplicationsJNCI Journal of the National Cancer Institute, 1989
- All ras proteins are polyisoprenylated but only some are palmitoylatedCell, 1989
- Control of Angiogenesis with Synthetic Heparin SubstitutesScience, 1989
- Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elementsNucleic Acids Research, 1989
- Effect of Mopidamol on Survival in Carcinoma of the Lung and Colon: Final Report of Veterans Administration Cooperative Study No. 188JNCI Journal of the National Cancer Institute, 1988
- Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.Journal of Clinical Oncology, 1986
- Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth FactorScience, 1984